Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: Effectiveness of an injection protocol based on the vascular anatomy of the nose

Laryngoscope

Volumn 122, Issue 6, 2012, Pages 1210-1214

  Dheyauldeen, Sinan ^a   Østertun Geirdal, Amy ^a,b   Osnes, Terje ^a   Vartdal, Liv Sofie ^a   Dollner, Ralph ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO METROPOLITAN UNIVERSITY   (Norway)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

bevacizumab; Epistaxis; hereditary hemorrhagic telangiectasia; intranasal; local treatment; Osler disease; quality of life; treatment technique; vascular anatomy of the nose

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN;

ADULT; AGED; BLOOD TRANSFUSION; CANTRIL SELF ANCHORING LADDER QUESTIONNAIRE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; EPISTAXIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NOSE; PRIORITY JOURNAL; PTERYGOPALATINE FOSSA; QUALITY OF LIFE; RENDU OSLER WEBER DISEASE; SHORT FORM 36; SLOTOSCH DISEAS SPECIFIC QOL QUESTIONNAIRE; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANESTHESIA, LOCAL; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION SCHEDULE; EPISTAXIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; NASAL CAVITY; NASAL MUCOSA; PILOT PROJECTS; PREMEDICATION; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861819813     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23303     Document Type: Conference Paper

References (35)

1. Folz BJ, Tennie J, Lippert BM, Werner JA,. Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 2005; 43: 40-46.
2. Harvey RJ, Kanagalingam J, Lund VJ,. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol 2008; 22: 182-187.
3. Pasculli G, Resta F, Guastamacchia E, Di GL, Suppressa P, Sabba C,. Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease. Qual Life Res 2004; 13: 1715-1723.
4. Rohrmeier C, Sachs HG, Kuehnel TS,. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 2012; 269: 531-536.
5. Lund VJ, Howard DJ,. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol 1999; 13: 319-322.
6. Hitchings AE, Lennox PA, Lund VJ, Howard DJ,. The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 2005; 19: 75-78.
7. Ichimura K, Kikuchi H, Imayoshi S, Yamauchi T, Ishikawa K,. Are patients with severe epistaxis caused by hereditary hemorrhagic telangiectasia satisfied with nostril closure surgery? Auris Nasus Larynx 2012; 39: 59-64.
8. Begbie ME, Wallace GM, Shovlin CL,. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 2003; 79: 18-24.
9. Shovlin CL,. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-219.
10. Sadick H, Sadick M, Gotte K, et al. Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures. Wien Klin Wochenschr 2006; 118: 72-80.
11. Sadick H, Hage J, Goessler U, et al. Does the genotype of HHT patients with mutations of the ENG and ACVRL1 gene correlate to different expression levels of the angiogenic factor VEGF? Int J Mol Med 2008; 22: 575-580.
12. Sadick H, Naim R, Sadick M, Hormann K, Riedel F,. Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia. Int J Mol Med 2005; 15: 591-596.
13. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-828.
14. Simonds J, Miller F, Mandel J, Davidson TM,. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119: 988-992.
15. Flieger D, Hainke S, Fischbach W,. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006; 85: 631-632.
16. Buscarini E, Manfredi G, Zambelli A,. Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution. Liver Transpl 2008; 14: 1685-1686.
17. Chen S, Karnezis T, Davidson TM,. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia- associated epistaxis. Laryngoscope 2011; 121: 644-646.
18. Davidson TM, Olitsky SE, Wei JL,. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010; 120: 432-435.
19. Karnezis TT, Davidson TM,. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121: 636-638.
20. Whitehead K, ed. 9th International Hereditary Hemorrhagic Telangiectasia Scientific Conference, May 20-24, 2011. Kemer, Antalya, Turkey. Hematol Rep. [serial online]. May 2011. Available at:.
21. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67.
22. Al-Deen S, Bachmann-Harildstad G,. A grading scale for epistaxis in hereditary haemorrhagic teleangectasia. Rhinology 2008; 46: 281-284.
23. Dheyauldeen S, Abdelnoor M, Bachmann-Harildstad G,. The natural history of epistaxis in patients with hereditary hemorrhagic telangiectasia in the Norwegian population: a cross-sectional study. Am J Rhinol Allergy 2011; 25: 214-218.
24. Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA,. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120: 838-843.
25. Snowk K, Kosiniski M, Grandek B, eds. SF-36 Health Survey Manual and Interpretation Guide. Cambridge, MA: New England Health Institute; 1993.
26. Wagner AK, Gandek B, Aaronson NK, et al. Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 925-932.
27. Cantril H,. The Pattern of Human Concerns. New Brunswick, NJ: Rutgers University Press; 1965.
28. Slotosch D, Koller M, Werner JA, Folz BJ,. Recurrent nosebleeds in patients with hereditary hemorrhagic telangiectasia [in German]. Dtsch Med Wochenschr 2006; 131: 535-539.
29. Geisthoff UW, Heckmann K, D'Amelio R, et al. Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 2007; 136: 726-733.
30. Ingrand I, Ingrand P, Gilbert-Dussardier B, et al. Altered quality of life in Rendu-Osler-Weber disease related to recurrent epistaxis. Rhinology 2011; 49: 155-162.
31. Karapantzos I, Tsimpiris N, Goulis DG, Van HH, Van CP, Danielides V,. Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire. Eur Arch Otorhinolaryngol 2005; 262: 830-833.
32. Lennox PA, Hitchings AE, Lund VJ, Howard DJ,. The SF-36 health status questionnaire in assessing patients with epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 2005; 19: 71-74.
33. Pfister M, Zalaman IM, Blumenstock G, Mauz PS, Baumann I,. Impact of genotype and mutation type on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. Acta Otolaryngol 2009; 129: 862-866.
34. Loaec M, Moriniere S, Hitier M, Ferrant O, Plauchu H, Babin E,. Psychosocial quality of life in hereditary haemorrhagic telangiectasia patients. Rhinology 2011; 49: 164-167.
35. Jorgensen G, Lange B, Wanscher JH, Kjeldsen AD,. Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 2011; 268: 1765-1770.